TWI795362B - 拮抗藥與免疫核查點阻礙藥而成之組合 - Google Patents

拮抗藥與免疫核查點阻礙藥而成之組合 Download PDF

Info

Publication number
TWI795362B
TWI795362B TW106122678A TW106122678A TWI795362B TW I795362 B TWI795362 B TW I795362B TW 106122678 A TW106122678 A TW 106122678A TW 106122678 A TW106122678 A TW 106122678A TW I795362 B TWI795362 B TW I795362B
Authority
TW
Taiwan
Prior art keywords
cyclopropane
carbonyl
phenyl
amino
cyano
Prior art date
Application number
TW106122678A
Other languages
English (en)
Chinese (zh)
Other versions
TW201806593A (zh
Inventor
吉田雄
正山彰子
高野裕嗣
Original Assignee
日商小野藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商小野藥品工業股份有限公司 filed Critical 日商小野藥品工業股份有限公司
Publication of TW201806593A publication Critical patent/TW201806593A/zh
Application granted granted Critical
Publication of TWI795362B publication Critical patent/TWI795362B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
TW106122678A 2016-07-07 2017-07-06 拮抗藥與免疫核查點阻礙藥而成之組合 TWI795362B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359504P 2016-07-07 2016-07-07
US62/359,504 2016-07-07

Publications (2)

Publication Number Publication Date
TW201806593A TW201806593A (zh) 2018-03-01
TWI795362B true TWI795362B (zh) 2023-03-11

Family

ID=60912958

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106122678A TWI795362B (zh) 2016-07-07 2017-07-06 拮抗藥與免疫核查點阻礙藥而成之組合
TW111107751A TWI805255B (zh) 2016-07-07 2017-07-06 拮抗藥與免疫核查點阻礙藥而成之組合的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111107751A TWI805255B (zh) 2016-07-07 2017-07-06 拮抗藥與免疫核查點阻礙藥而成之組合的用途

Country Status (21)

Country Link
US (1) US11065226B2 (https=)
EP (1) EP3482760B1 (https=)
JP (2) JP6323629B1 (https=)
KR (1) KR102473601B1 (https=)
CN (1) CN109475520B (https=)
AU (1) AU2017292522B2 (https=)
CA (1) CA3029611A1 (https=)
DK (1) DK3482760T3 (https=)
ES (1) ES2900306T3 (https=)
HU (1) HUE057799T2 (https=)
IL (1) IL264063B (https=)
MX (1) MX385428B (https=)
MY (1) MY197673A (https=)
PH (1) PH12019500002B1 (https=)
PL (1) PL3482760T3 (https=)
PT (1) PT3482760T (https=)
RU (1) RU2748731C2 (https=)
SG (1) SG11201811591UA (https=)
TW (2) TWI795362B (https=)
WO (1) WO2018008711A1 (https=)
ZA (1) ZA201900060B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3255624B2 (ja) 1998-07-03 2002-02-12 日本電信電話株式会社 コネクタプラグおよび光コネクタ
NZ733575A (en) * 2015-01-09 2022-10-28 Ono Pharmaceutical Co Tricyclic spiro compound
AU2018255300B2 (en) * 2017-04-18 2021-10-28 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
JP7159007B2 (ja) 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
US20200352906A1 (en) * 2018-02-05 2020-11-12 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
US10973834B2 (en) * 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
IL277963B2 (en) 2018-04-17 2024-09-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3722319A1 (en) * 2019-04-09 2020-10-14 Rottapharm Biotech S.r.l. Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
WO2020242773A1 (en) * 2019-05-31 2020-12-03 Clear Creek Bio, Inc. Methods of promoting differentiation of myeloid-derived suppressor cells using inhibitors of dihydroorotate dehydrogenase
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
KR20220122696A (ko) * 2019-12-25 2022-09-02 니뽄 신야쿠 가부시키가이샤 면역 체크포인트 저해제와 병용으로 이용하는 항종양약
WO2021183640A1 (en) * 2020-03-10 2021-09-16 Emory University Methods of treating cancer using checkpoint inhibitors in combination with purine cleaving enzymes
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
CN117377656A (zh) * 2021-05-28 2024-01-09 南京明德新药研发有限公司 苯并螺杂环衍生物及其应用
US20250002448A1 (en) * 2021-09-21 2025-01-02 Merck Sharp & Dohme Llc Allosteric modulators of nicotinic acetylcholine receptors
WO2023198060A1 (zh) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 蛋白酶体抑制剂与抗pd-1抗体的药物组合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179615A1 (en) * 2014-05-23 2015-11-26 Eisai R&D Management Co., Ltd Combination therapies for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1071648A2 (en) 1998-03-13 2001-01-31 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
CA2420042A1 (en) 2000-08-22 2003-02-18 Mikio Ogawa Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
NZ733575A (en) 2015-01-09 2022-10-28 Ono Pharmaceutical Co Tricyclic spiro compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179615A1 (en) * 2014-05-23 2015-11-26 Eisai R&D Management Co., Ltd Combination therapies for the treatment of cancer

Also Published As

Publication number Publication date
AU2017292522A9 (en) 2019-01-31
KR20190026736A (ko) 2019-03-13
PL3482760T3 (pl) 2022-02-07
IL264063B (en) 2022-02-01
JP2018100297A (ja) 2018-06-28
US20190255013A1 (en) 2019-08-22
JP7020218B2 (ja) 2022-02-16
WO2018008711A1 (ja) 2018-01-11
JPWO2018008711A1 (ja) 2018-07-05
SG11201811591UA (en) 2019-01-30
AU2017292522B2 (en) 2022-10-13
CN109475520B (zh) 2021-05-14
TW202224675A (zh) 2022-07-01
ES2900306T3 (es) 2022-03-16
PT3482760T (pt) 2021-12-15
RU2018146479A (ru) 2020-08-07
NZ749540A (en) 2024-09-27
KR102473601B1 (ko) 2022-12-01
PH12019500002B1 (en) 2024-06-28
RU2018146479A3 (https=) 2020-11-23
ZA201900060B (en) 2019-09-25
CN109475520A (zh) 2019-03-15
AU2017292522A1 (en) 2019-01-17
BR112019000243A2 (pt) 2019-04-16
JP6323629B1 (ja) 2018-05-16
EP3482760B1 (en) 2021-11-10
TWI805255B (zh) 2023-06-11
CA3029611A1 (en) 2018-01-11
MX2018015567A (es) 2019-06-06
DK3482760T3 (da) 2022-01-03
EP3482760A1 (en) 2019-05-15
IL264063A (en) 2019-01-31
HUE057799T2 (hu) 2022-06-28
US11065226B2 (en) 2021-07-20
RU2748731C2 (ru) 2021-05-31
MY197673A (en) 2023-07-03
PH12019500002A1 (en) 2019-10-21
MX385428B (es) 2025-03-04
TW201806593A (zh) 2018-03-01
EP3482760A4 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
TWI795362B (zh) 拮抗藥與免疫核查點阻礙藥而成之組合
JP6760249B2 (ja) 三環性スピロ化合物
JP6922712B2 (ja) 医薬用途
HK40002610A (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
HK40002610B (zh) 包含ep4拮抗剂和免疫检查点抑制剂的组合
BR112019000243B1 (pt) Medicamento compreendendo uma combinação de um composto antagonista do ep4 e um inibidor de checkpoint imunológico, bem como uso da referida combinação para o tratamento de câncer
NZ789384A (en) Combination comprising EP4 antagonist and immune checkpoint inhibitor
HK1239657B (zh) 三环螺环化合物